mRNA can be synthesized outside of human cells and manufactured easily on the industrial scale. This enabled us to synthesis desired mRNAs to be delivered into our body and produce required proteins. Once delivered into our cells, these mRNAs guide protein production and can be used to rectify cellular functions or to educate the immune system to trigger proper immune responses like vaccines do.
mRNA coding sequence and its core components determine the stability of binding between mRNA and the ribosome, eventually affecting translation efficiency and duration. Through rational sequence design and optimization, we have found the optimal ribosome-binding sequences to achieve more efficient and long-lasting protein translation.
Faced with the challenge of delivering mRNA into the correct cell, mRNA carriers have long been unable to maximize mRNA as a therapeutic tool capable of guiding cells to generate disease-fighting proteins. Innorna was able to develop the proprietary diversity oriented LNP platform for safely and effectively delivering the mRNA into the right cells and commercialize this innovative technology. This enables a wide range of potential therapeutic strategies that we are using to advance a diversified portfolio of mRNA medicine pipelines．
Diversity-Oriented Lipid Library (DOLL)
Molecular diversity is the key to finding new functionalities of lipid nanoparticles. Innorna is committed to building a diversity-oriented lipid library (DOLL) to explore new functions of lipids, such as tissue specific delivery, and molecules with low immunogenicity. By employing various chemical methods to build up the core structure of DOLL, we maintain a higher molecular diversity and have a greater chance of finding new functional lipids than combinatorial libraries.